344 related articles for article (PubMed ID: 17496417)
1. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.
Winblad B; Jones RW; Wirth Y; Stöffler A; Möbius HJ
Dement Geriatr Cogn Disord; 2007; 24(1):20-7. PubMed ID: 17496417
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
3. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients.
Ferris S; Ihl R; Robert P; Winblad B; Gatz G; Tennigkeit F; Gauthier S
Alzheimers Dement; 2009 Sep; 5(5):369-74. PubMed ID: 19751915
[TBL] [Abstract][Full Text] [Related]
4. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
5. Memantine in moderate-to-severe Alzheimer's disease.
Reisberg B; Doody R; Stöffler A; Schmitt F; Ferris S; Möbius HJ;
N Engl J Med; 2003 Apr; 348(14):1333-41. PubMed ID: 12672860
[TBL] [Abstract][Full Text] [Related]
6. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
Gauthier S; Loft H; Cummings J
Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
[TBL] [Abstract][Full Text] [Related]
7. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
8. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
Pomara N; Ott BR; Peskind E; Resnick EM
Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
[TBL] [Abstract][Full Text] [Related]
9. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
Feldman HH; Schmitt FA; Olin JT;
Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
[TBL] [Abstract][Full Text] [Related]
10. Memantine for treatment of moderate to severe Alzheimer's disease.
Perras C
Issues Emerg Health Technol; 2005 Mar; (64):1-4. PubMed ID: 15762015
[TBL] [Abstract][Full Text] [Related]
11. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
Gauthier S; Wirth Y; Möbius HJ
Int J Geriatr Psychiatry; 2005 May; 20(5):459-64. PubMed ID: 15852444
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
[TBL] [Abstract][Full Text] [Related]
13. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
[TBL] [Abstract][Full Text] [Related]
14. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD.
Hellweg R; Wirth Y; Janetzky W; Hartmann S
Int J Geriatr Psychiatry; 2012 Jun; 27(6):651-6. PubMed ID: 22513699
[TBL] [Abstract][Full Text] [Related]
16. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
Grossberg GT; Pejović V; Miller ML; Graham SM
Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105
[TBL] [Abstract][Full Text] [Related]
17. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis.
Livingston G; Katona C
Int J Geriatr Psychiatry; 2004 Oct; 19(10):919-25. PubMed ID: 15449303
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
Bullock R
Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
[TBL] [Abstract][Full Text] [Related]
19. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.
van Dyck CH; Tariot PN; Meyers B; Malca Resnick E;
Alzheimer Dis Assoc Disord; 2007; 21(2):136-43. PubMed ID: 17545739
[TBL] [Abstract][Full Text] [Related]
20. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial.
Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Ohbayashi T
Dement Geriatr Cogn Disord; 2008; 25(5):399-407. PubMed ID: 18391486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
